Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Non-coding RNAs in AMI Patients: A Substudy of the PACMAN-AMI Trial.

Yasushi UekiJonas HänerSylvain LosdatGiuseppe GargiuloHiroki ShibutaniSarah BärTatsuhiko OtsukaRaminta KavaliauskaiteVera MitterFabrice TemperliDavid SpirkStefan StorteckyGeorge SiontisMarco ValgimigliStephan WindeckerClemens GutmannKonstantinos C KoskinasManuel MayrLorenz Raber

Published in: Thrombosis and haemostasis (2023)

Among AMI patients receiving DAPT with a potent P2Y12 inhibitor, alirocumab had no significant effect on platelet reactivity as assessed by PRU and platelet-derived non-coding RNAs.

Keyphrases

high intensity
acute myocardial infarction
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
coronary artery disease
heart failure
randomized controlled trial
phase ii
left ventricular
patient reported outcomes
anti inflammatory